Document Detail


Transforming growth factor-beta1 and prostate cancer.
MedLine Citation:
PMID:  10903068     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Transforming growth factor-beta1 (TGF-beta1) is an important regulator of the normal and malignant prostate. In the non-malignant prostate, TGF-beta1 stimulates cell differentiation, inhibits epithelial cell proliferation and induces epithelial cell death. TGF-beta1 is secreted into semen and here it is an important immunosuppressive factor. Prostate cancer cells express high levels of TGF-beta1 and it seems to enhance prostate cancer growth and metastasis by stimulating angiogenesis and by inhibiting immune responses directed against tumour cells. Prostate cancer cells frequently lose their TGF-beta receptors and acquire resistance to the anti-proliferative and pro-apoptotic effects of TGF-beta1. Accordingly, high expression of TGF-beta1 and loss of TGF-beta receptor expression have been associated with a particularly bad prognosis in human prostate cancer patients. TGF-beta1 also seems to be a mediator of castration-induced apoptosis in androgen dependent normal and malignant prostate epithelial cells. The ability of some prostate tumours to avoid castration-induced apoptosis is however not simply due to loss of TGF-beta receptor type I or II expression in the tumour cells, but may also be related to an inability of these cells to up-regulate TGF-beta receptor levels in response to castration or possibly due to defects downstream of the receptors. Short-term therapy-induced changes in the TGF-beta system in prostate tumours can probably be used to predict the long-term response to androgen ablation treatment. Further investigations into the TGF-beta system in the prostate are, however, needed to elucidate how alterations in this system affect the behaviour of prostate tumours, and if this system can be manipulated for therapeutical purposes.
Authors:
P Wikström; A Bergh; J E Damber
Related Documents :
18025068 - Pancreatic cancer regression by intratumoural injection of live streptococcus pyogenes ...
1418728 - Mhc antigens and cancer: implications for t-cell surveillance.
17223738 - Cysteine cathepsins: regulators of antitumour immune response.
20664588 - Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mes...
22032908 - Anoikis potential of entameba histolytica secretory cysteine proteases: evidence of con...
18817308 - Dynamic differential regulation of innate immune transcripts during the infection of al...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Scandinavian journal of urology and nephrology     Volume:  34     ISSN:  0036-5599     ISO Abbreviation:  Scand. J. Urol. Nephrol.     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2000-12-27     Completed Date:  2000-12-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0114501     Medline TA:  Scand J Urol Nephrol     Country:  SWEDEN    
Other Details:
Languages:  eng     Pagination:  85-94     Citation Subset:  IM    
Affiliation:
Department of Surgical and Perioperative Sciences, Umeå University, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Disease Progression
Gene Expression Regulation, Neoplastic
Humans
Male
Orchiectomy
Prognosis
Prostatic Neoplasms / genetics,  pathology*,  therapy
RNA, Messenger / biosynthesis
Receptors, Transforming Growth Factor beta / genetics
Transforming Growth Factor beta / physiology*
Treatment Outcome
Chemical
Reg. No./Substance:
0/RNA, Messenger; 0/Receptors, Transforming Growth Factor beta; 0/Transforming Growth Factor beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular tracheobronchial compression syndromes-- experience in surgical treatment and literature re...
Next Document:  Prospective registration of all patients in a geographical region with newly diagnosed bladder carci...